The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher

The Mayne Pharma share price is surging higher today, up 7.58% in late afternoon trading. Are investors sensing value?
The post The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher appeared first on Motley Fool Australia. –

shares higher, growth shares

The Mayne Pharma Group Ltd (ASX: MYX) share price is leaping higher today, up 7.58% in late afternoon trading.

This will come as welcome news to shareholders who saw Maybe Pharma’s share price fall 11% in the 4 days following the release of its full year 2020 financial results on 21 August. Investors sold off shares after the company reported a 13% fall in revenue and a net loss after tax of $93 million.

Mayne Pharma’s share price, like most shares on the ASX, was savaged during the COVID-19 panic selling earlier this year, falling 59% from 20 January through to the low on 19 March. Since that low, the Mayne Pharma share price has rebounded to gain 74%. Year-to-date it’s down 23%.

By contrast the All Ordinaries Index (ASX: XAO) is down 11% in 2020.

At the current price of 36 cents per share, Mayne Pharma has a market cap of $596 million.

What does Mayne Pharma do?

Mayne Pharma Group is a technology driven pharmaceutical company. It applies its drug delivery expertise to commercialise branded and generic pharmaceuticals with expertise in formulating complex oral and topical dose forms. The company also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has product development and manufacturing facilities in Salisbury, Australia and Greenville, North Carolina in the United States. The company has a global reach through its distribution partners in Australia, North America, Europe and Asia.

Mayne Pharma shares first traded on the ASX in 2007.

Why is the Mayne Pharma share price up today?

The Mayne Pharma share price is surging today on no major breaking news.

Large daily share price swings aren’t all that unusual for Mayne Pharma. Today’s surge is likely due to several factors.

Following the recent selloff, investors are seeing value at the company’s current share price. While its revenues were down over FY19, its international sales grew 4% year-on-year.

Investors may also be buying shares ahead of any news on Mayne Pharma’s Nextstellis contraceptive product. The company has already received US FDA filing acceptance and is in the process of completing the licensing procedures in the US and here in Australia.

With other projects in the pipeline also progressing, today’s share price rise could indicate good news to come. Or, at least, expectations thereof.

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The Mayne Pharma (ASX:MYX) share price leaps almost 8% higher appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!